Show simple item record

dc.contributor.authorClamp, Andrew R
dc.contributor.authorDanson, Sarah
dc.contributor.authorNguyen, Huy
dc.contributor.authorCole, David
dc.contributor.authorClemons, Mark
dc.date.accessioned2009-08-25T11:02:59Z
dc.date.available2009-08-25T11:02:59Z
dc.date.issued2004-10
dc.identifier.citationAssessment of therapeutic response in patients with metastatic bone disease. 2004, 5 (10):607-16 Lancet Oncol.en
dc.identifier.issn1470-2045
dc.identifier.pmid15465464
dc.identifier.doi10.1016/S1470-2045(04)01596-7
dc.identifier.urihttp://hdl.handle.net/10541/78441
dc.description.abstractMetastatic bone disease is common in cancer patients and causes substantial disease-related morbidity and mortality. However, several effective treatments are available for the management of these patients. Bisphosphonates, which inhibit osteoclast-mediated resorption of bone matrix, are especially important because they decrease the incidence of skeletal-related events in many tumour types and can complement antineoplastic therapies. At present, assessment of treatment for bone metastases is hindered by a lack of effective, rapid methods to measure disease response. We discuss the difficulties of current measures of response assessment and describe the development of new radiological and biochemical markers of bone metastases. Assays that detect type I collagen telopeptides as markers of bone resorption seem to be most promising at present.
dc.language.isoenen
dc.subjectBone Canceren
dc.subjectBiological Tumour Markersen
dc.subject.meshAbsorptiometry, Photon
dc.subject.meshBone Neoplasms
dc.subject.meshBone Remodeling
dc.subject.meshHumans
dc.subject.meshMagnetic Resonance Imaging
dc.subject.meshTomography, Emission-Computed
dc.subject.meshTomography, X-Ray Computed
dc.subject.meshTreatment Outcome
dc.subject.meshTumor Markers, Biological
dc.titleAssessment of therapeutic response in patients with metastatic bone disease.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK, Department of Medical Oncology, Christie Hospital, Manchester, UK.en
dc.identifier.journalThe Lancet Oncologyen
html.description.abstractMetastatic bone disease is common in cancer patients and causes substantial disease-related morbidity and mortality. However, several effective treatments are available for the management of these patients. Bisphosphonates, which inhibit osteoclast-mediated resorption of bone matrix, are especially important because they decrease the incidence of skeletal-related events in many tumour types and can complement antineoplastic therapies. At present, assessment of treatment for bone metastases is hindered by a lack of effective, rapid methods to measure disease response. We discuss the difficulties of current measures of response assessment and describe the development of new radiological and biochemical markers of bone metastases. Assays that detect type I collagen telopeptides as markers of bone resorption seem to be most promising at present.


Files in this item

This item appears in the following Collection(s)

Show simple item record